Colorectal cancer (metastatic) - bevacizumab and cetuximab (TA118) (partially updated by TA242)
Fast, easy summary view of NICE guidance on 'colorectal cancer'
This guidance has been partially updated by TA242 Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
Bevacizumab in combination with 5-fluorouracil plus folinic acid, with or without irinotecan, is not recommended for people with metastatic colorectal cancer who have not been treated before.
Cetuximab in combination with irinotecan is not recommended for people with metastatic colorectal cancer who have had previous treatment for the cancer that also included irinotecan.
Consultants should not stop prescribing bevacizumab or cetuximab for people who were already taking it when the guidance was issued. These patients should be able to carry on taking bevacizumab or cetuximab until they and their consultants decide that it is the right time to stop treatment.
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: colorectal cancer
This page was last updated: 10 April 2013
Information for the public
Implementation tools and resources
See this guidance in practice
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.